Diplomat Pharmacy Inc (NYSE:DPLO) – Equities research analysts at William Blair cut their FY2019 earnings per share (EPS) estimates for Diplomat Pharmacy in a report released on Tuesday. William Blair analyst J. Kreger now forecasts that the company will post earnings of $1.21 per share for the year, down from their prior forecast of $1.52. William Blair also issued estimates for Diplomat Pharmacy’s FY2020 earnings at $1.55 EPS.
Other analysts also recently issued research reports about the company. Needham & Company LLC raised their price objective on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Monday, January 8th. Deutsche Bank initiated coverage on Diplomat Pharmacy in a research report on Monday, December 4th. They issued a “buy” rating and a $22.00 price objective for the company. Lake Street Capital initiated coverage on Diplomat Pharmacy in a research report on Friday, February 9th. They issued a “buy” rating and a $35.00 price objective for the company. Leerink Swann set a $30.00 price objective on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $24.79.
Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, February 26th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.02. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a return on equity of 8.89% and a net margin of 0.35%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 EPS.
Several institutional investors have recently bought and sold shares of the stock. Envestnet Asset Management Inc. lifted its position in shares of Diplomat Pharmacy by 27.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,655 shares of the company’s stock worth $334,000 after buying an additional 3,550 shares during the period. Phocas Financial Corp. lifted its position in shares of Diplomat Pharmacy by 142.9% during the 4th quarter. Phocas Financial Corp. now owns 663,187 shares of the company’s stock worth $13,310,000 after buying an additional 390,168 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Diplomat Pharmacy during the 4th quarter worth approximately $448,000. Macquarie Group Ltd. bought a new position in shares of Diplomat Pharmacy during the 4th quarter worth approximately $315,000. Finally, Vident Investment Advisory LLC lifted its position in shares of Diplomat Pharmacy by 6.5% during the 4th quarter. Vident Investment Advisory LLC now owns 150,504 shares of the company’s stock worth $3,021,000 after buying an additional 9,196 shares during the period. Institutional investors and hedge funds own 73.44% of the company’s stock.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.